Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
109.7 USD | +0.77% | +0.71% | -10.84% |
Financials (USD)
Sales 2024 * | 4.09B | Sales 2025 * | 4.39B | Capitalization | 6.84B |
---|---|---|---|---|---|
Net income 2024 * | 475M | Net income 2025 * | 648M | EV / Sales 2024 * | 2.4 x |
Net Debt 2024 * | 3B | Net Debt 2025 * | 1.61B | EV / Sales 2025 * | 1.93 x |
P/E ratio 2024 * |
16.5
x | P/E ratio 2025 * |
11.2
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.18% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | +0.77% | ||
1 week | +0.71% | ||
Current month | -8.93% | ||
1 month | -9.97% | ||
3 months | -8.69% | ||
6 months | -14.71% | ||
Current year | -10.84% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 215 M€ | +11.92% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 109.7 | +0.77% | 376,841 |
24-04-22 | 108.8 | -1.01% | 514,011 |
24-04-19 | 109.9 | +0.61% | 756,914 |
24-04-18 | 109.3 | +2.03% | 564,463 |
24-04-17 | 107.1 | -1.65% | 592,713 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.84% | 6.84B | |
+27.92% | 672B | |
+27.22% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.45% | 217B | |
+5.41% | 199B | |
-8.47% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- JAZZ Stock